<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The application of myeloablative Allo-SCT is limited by its associated morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Reduced-intensity conditioning regimens attempt to diminish these, but are associated with a higher risk of disease relapse </plain></SENT>
<SENT sid="2" pm="."><plain>Given the evidence of activity of clofarabine and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), we explored a novel reduced-intensity conditioning regimen based on this backbone </plain></SENT>
<SENT sid="3" pm="."><plain>Patients received clofarabine 40 mg/m(2) i.v. on days -6 to -2, <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 1 g/m(2) i.v. on days -6 to -2 and anti-thymocyte globulin (ATG) 1 mg/kg on day -4 and 2.5 mg/kg x 2 days on days -3 and -2 </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients were enrolled </plain></SENT>
<SENT sid="5" pm="."><plain>Their median age was 54 years; three were with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and four with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The median duration of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> was 14 days and that of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> was 22 days </plain></SENT>
<SENT sid="7" pm="."><plain>Toxicities included <z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand-foot syndrome</z:e> (57% grade 2), elevated alanine aminotransferase (ALT) (57% grade 3), elevated <z:chebi fb="0" ids="29995">aspartate</z:chebi> aminotransferase (AST) (86% grade 3) and <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> (29% grade 3-5) </plain></SENT>
<SENT sid="8" pm="."><plain>No <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was observed </plain></SENT>
<SENT sid="9" pm="."><plain>Enrollment to the trial was halted after three of the first seven patients expired on days +15, +26 and +32 </plain></SENT>
<SENT sid="10" pm="."><plain>Three of the four surviving patients have relapsed with a median <z:chebi fb="1" ids="18284">TTP</z:chebi> of 152 days </plain></SENT>
<SENT sid="11" pm="."><plain>This regimen was not sufficiently immunosuppressive to ensure engraftment, and was associated with substantial morbidity and mortality </plain></SENT>
</text></document>